Revista de la Sociedad Peruana de Medicina Interna - Vol. 12  N.º 4, 1999
 

BIBLIOGRAFÍA

  1. Harris E. Clinical features of Rheumatoid Arthritis. In: Kelley W, Harris E, Ruddy, Sledge (C. Eds). Textbook of Rheumatology, 5.ª ed., WB Saunders Co., Philadelphia, 1997; pp 898-932.
  2. Moreland L. Inhibitors of TNF for Rheumatoid Arthirtis. J. Rheumatol 1999; 26 suppl. 57: 715.
  3. Kavanaugh A. antitumor necrosis factor monoclonal antibody therapy for RA. Rheum Dis Clin North Am 1998; 24: 593-614.
  4. Moreland L, Margolies G, Heck L, et al. Recombinant soluble TNF receptor (p80) fusion protein: toxicity and dose finding trial in refractory RA. J. Rheumatol 1996; 23: 1849-55.
  5. Weinblatt M, Kremer J, Banklmrst A, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor. Fc fusion protein in patients with RA receiving methotrexate. N Engl J. Med. 1999; 340: 253-9.
  6. Moreland L. Soluble TNF receptor (p75) fusion protein as a therapy for RA. Rheum Dis Clin North Am 1998; 24: 579-91.
  7. Felson D, Anderson J, beers M, et al. American College of Rheumatology preliminary definition of improvement in ARA. Arthr. Rheum. 1995; 38: 727-35.
  8. Moreland L, Baumagartner S, Schiff M, et al. Treatment of RA with a recombinant human TNF receptor (p75)-Fc fusion protein. N. Engl. J. med. 1997; 337: 141-7.
  9. Moreland L, Baumgarther S, Tindall T, et al. Long term safety and efficacy of TNF receptor (p75)-Fc Fusion protein in DMARD refractory RA (abstract). Arthr Rheum 1998; suppl 44: S364.
  10. Moreland L, Schiff M, Baumgartner S, et al. Etanercept therapy in RA. A randomized controlled trial. Ann. Intern. Med. 1999; 130: 478-86.
  11. Elliott M, Maim R, Feldman M, et al. randomised double blind comparison of chimeric monoclonal antibody to TNF versus placebo in RA., Lancet 1994; 344: 1105-10.
  12. Elliott M, Maim R, Feldman M, et al. Repeated therapy with monoclonal antibody to TNF in patients with RA. Lancet 1994; 344: 1125-7.
  13. Maim R, Bredreld F, Kalden J, et al. Therapeutic efficacy of multiple intravenous infusions of anti TNF monoclonal antibody combined low dose weekly methotrexate in RA. Arthr Rheum 1998; 41: 1552-63.
  14. O'Dell J, Haire C, Erikson N, et al. Treatment of RA with methotrexate alone, suffasalazine or hydroxichloroquine, or a combination of all three medications. N. Engl. J. Med. 1996; 334: 1287-91.

 

Regresar